Effect of Trillium tschonoskii Maxim. on the Contraction of Uterine Smooth Muscle
-
摘要:
目的 研究头顶一颗珠(Trillium tschonoskii Maxim.)的子宫平滑肌收缩作用及其物质基础。 方法 运用大鼠离体子宫平滑肌试验方法,对头顶一颗珠分离后的不同馏分进行活性筛选,采用现代波谱技术鉴定有效部位的主要成分。 结果 筛选出头顶一颗珠引起子宫平滑肌收缩的活性部位,并鉴定了其3个主要成分,均为偏诺皂苷。 结论 头顶一颗珠具有显著的子宫平滑肌收缩作用,该作用的活性成分为偏诺皂苷。 Abstract:Objective To study the chemical constituents of the rhizomes of Trillium tschonoskii that cause uterine smooth muscle contraction. Methods The isolated rat uterine smooth muscle test method was used to screen the activity of different extracted parts of Trillium tschonoskii. Modern spectroscopy techniques were used to identify the main components of the effective parts. Results The main active part of T.tschonoskii that caused uterine smooth muscle contraction was screened, and three main components were identified as pennogenin saponins from this part. Conclusion T.tschonoskii has the effect of inducing uterine smooth muscle contraction, and the main active ingredient of this effect was pennogenin saponins. -
Key words:
- Trillium tschonoskii /
- Uterine smooth muscle /
- Chemical composition /
- Pennogenin saponins
-
表 1 受试药对大鼠离体子宫收缩频率(次/10 min)的影响 (
$\bar x \pm s $ )Table 1. The effect of the medicine on the frequency of isolated rat uterine contractions (times/10 min) (
$\bar x \pm s $ )组别 n 浓度(g/mL) 给药前 1×10−7 3×10−7 1×10−6 3×10−6 1×10−5 3×10−5 1×10−4 阳性 7 4.83 ± 1.47 4.83 ± 1.17 5.33 ± 1.51 6.00 ± 1.27 5.67 ± 0.52 6.67 ± 0.52 7.33 ± 1.75△ 8.83 ± 1.71* F1 6 6.50 ± 1.64 6.00 ± 1.10 6.67 ± 0.82 5.83 ± 0.75 5.17 ± 0.98 5.17 ± 1.17 4.50 ± 0.84△ 4.33 ± 0.82* F2 6 5.17 ± 0.98 5.33 ± 0.82 4.83 ± 0.98 5.17 ± 1.17 4.67 ± 1.03 4.50 ± 1.05 4.67 ± 1.03 5.17 ± 1.47 F3 7 6.57 ± 0.98 6.43 ± 1.40 6.29 ± 1.70 5.86 ± 1.68 5.71 ± 1.60 5.71 ± 1.60 5.71 ± 1.25 5.86 ± 1.68 F4 6 5.67 ± 1.86 5.33 ± 1.97 5.5 ± 2.34 4.67 ± 2.34 4.33 ± 1.97 4.67 ± 2.25 4.50 ± 2.07 5.00 ± 2.10 F5 8 7.38 ± 1.85 7.25 ± 1.67 6.50 ± 1.20 6.63 ± 1.19 6.38 ± 1.30 6.38 ± 1.30 6.13 ± 0.99 6.25 ± 1.03 F6 6 4.83 ± 1.94 4.83 ± 1.60 4.83 ± 1.60 4.83 ± 1.60 6.17 ± 1.60 8.17 ± 1.47△ 9.67 ± 2.25* 10.50 ± 2.07* 与给药前相比,△P < 0.05,*P < 0.01。 表 2 受试药对大鼠离体子宫平滑肌收缩强度(g)的影响(
$\bar x \pm s $ )Table 2. The effect of the medicine on the contraction strength (g) of rat uterine smooth muscle in vitro (
$\bar x \pm s $ )组别 n 浓度(g/mL) 给药前 1×10−7 3×10−7 1×10−6 3×10−6 1×10−5 3×10−5 1×10−4 阳性 6 3.21 ± 0.54 2.88 ± 0.41 2.87 ± 0.42 3.02 ± 0.57 2.99 ± 0.48 3.31 ± 0.59 3.92 ± 0.66 4.52 ± 0.45* F1 6 3.23 ± 0.92 3.12 ± 0.91 3.08 ± 0.75 2.74 ± 0.74 2.95 ± 0.81 2.95 ± 0.79 2.92 ± 0.66 2.44 ± 0.70 F2 6 3.53 ± 1.40 3.47 ± 1.47 3.72 ± 1.48 3.77 ± 1.47 3.73 ± 1.60 3.48 ± 1.64 3.28 ± 1.78 2.76 ± 1.88 F3 6 3.66 ± 2.05 3.49 ± 2.06 3.67 ± 1.61 3.24 ± 1.20 3.06 ± 1.19 2.31 ± 0.92 2.42 ± 1.11 2.08 ± 1.15 F4 6 4.70 ± 0.80 4.80 ± 0.76 4.32 ± 0.81 4.23 ± 0.84 4.16 ± 0.79 3.53 ± 0.67 3.16 ± 0.60△ 2.70 ± 0.72△ F5 6 4.87 ± 1.45 4.80 ± 1.51 4.49 ± 1.58 4.75 ± 1.76 4.39 ± 1.54 4.57 ± 1.66 4.57 ± 1.57 4.43 ± 1.61 F6 6 2.55 ± 0.56 2.61 ± 0.57 2.64 ± 0.76 2.58 ± 0.75 2.87 ± 0.53 3.00 ± 0.60 3.43 ± 0.61 4.46 ± 0.62* 与给药前相比,△P < 0.05,*P < 0.01。 表 3 受试药对大鼠离体子宫平滑肌活动力的影响(
$\bar x \pm s $ )Table 3. The effect of the medicine on the motility of isolated rat uterine smooth muscle (
$\bar x \pm s $ )组别 n 浓度(g/mL) 给药前 1×10−7 3×10−7 1×10−6 3×10−6 1×10−5 3×10−5 1×10−4 阳性 6 15.61 ± 5.76 13.73 ± 3.10 15.02 ± 3.69 17.87 ± 4.13 16.88 ± 2.85 22.11 ± 4.32 28.96 ± 9.10* 39.67 ± 7.04* F1 6 21.89 ± 10.71 19.2 ± 8.20 20.79 ± 6.86 16.10 ± 5.82 15.47 ± 6.45 15.27 ± 6.01 12.89 ± 2.97 10.35 ± 2.72△ F2 6 17.77 ± 7.02 18.29 ± 8.14 17.02 ± 5.05 19.52 ± 9.03 17.25 ± 8.66 14.90 ± 6.90 14.97 ± 9.23 12.75 ± 8.20 F3 6 23.76 ± 12.30 21.77 ± 12.10 22.87 ± 10.63 18.42 ± 6.37 17.40 ± 6.91 13.25 ± 5.78 13.67 ± 6.41 11.82 ± 6.52 F4 6 25.76 ± 5.72 24.86 ± 6.81 23.08 ± 7.56 19.18 ± 7.98 17.63 ± 6.93 15.72 ± 5.93 14.32 ± 5.96* 13.81 ± 7.56* F5 6 37.59 ± 20.06 36.19 ± 18.13 30.51 ± 15.76 32.36 ± 15.16 28.90 ± 14.25 30.12 ± 15.12 28.89 ± 13.82 28.50 ± 13.70 F6 6 12.22 ± 5.06 12.64 ± 5.23 12.88 ± 6.30 12.64 ± 6.16 18.22 ± 8.32 24.65 ± 7.42△ 33.25 ± 9.80* 46.55 ± 9.99* 与给药前相比,△P<0.05,*P<0.01。 -
[1] 国家中医药管理局中华本草编委会. 中华本草第8册[M]. 上海: 上海科技出版社, 1999: 174. [2] 欧阳俊摇,邹海艳,李慢中,等. 延龄草的化学成分和药理作用研究进展[J]. 时珍国医国药,2016,27(2):433-437. [3] 赵银萍,杜喜春,付洪冰. 延龄草研究进展综述[J]. 安徽农学通报,2017,23(16):127-139. doi: 10.3969/j.issn.1007-7731.2017.16.049 [4] 熊秋杨,辛光,李世一,等. 延龄草皂苷对小鼠急性胰腺炎和相关肺损伤的影响[J]. 华西药学杂志,2019,34(6):587-591. [5] 王先丽,任丹,詹光杰,等. 延龄草总皂苷对LPS诱导炎症大鼠的抗炎效果[J]. 基因组学与应用生物学,2019,38(8):3698-3705. [6] 王金龄,喻玲玲,邓晓卓,等. 延龄草皂苷抗肿瘤作用机制的研究进展[J]. 生命的化学,2018,38(2):224-228. [7] 李淑琪,胡凡,文安,等. 延龄草甾体皂苷抗大鼠急性心肌缺血有效成分的研究[J]. 江西中医药大学学报,2021,33(1):89-93. [8] 夏德尧,张桃,陈颖,等. 延龄草总皂苷对D-半乳糖诱导的SD大鼠心肌线粒体自噬的影响[J]. 中国药理学与毒理学杂志,2021,35(8):582-587. [9] 赵振虎,李建勇,苑晓玲,等. 宫血宁对大鼠离体子宫收缩作用的研究[J]. 解放军药学学报,2004,20(2):41-44. [10] 赵振虎,李建勇,苑晓玲,等. 皂苷提取物宫血宁缩宫作用与细胞外钙内流关系的研究[J]. 中国药物与临床,2005,5(6):415-417. doi: 10.3969/j.issn.1671-2560.2005.06.004 [11] 杨印军. 延龄草的化学成分研究[D]. 北京: 北京协和医学院硕士论文, 2017. [12] 杨杰. 中药延龄草的活性成分研究[D]. 广东: 广东药科大学硕士论文, 2018. [13] 李慧敏,潘宪伟,梅其炳,等. 延龄草化学成分的分离与鉴定[J]. 沈阳药科大学学报,2013,30(7):511-515. [14] 傅涛,王丽梅,赵振虎,等. 宫血宁胶囊引起大鼠子宫平滑肌收缩及其初步影响机制研究[J]. 武警医学,2017,28(6):557-559. doi: 10.3969/j.issn.1004-3594.2017.06.006 [15] 郭琳. 中药甾体皂苷引起子宫平滑肌收缩的化学基础及其分子机制研究[D]. 北京: 中国人民解放军军事医学科学院硕士论文, 2008. [16] 段宝忠,马维思,刘玉雨,等. 滇重楼无公害栽培关键技术[J]. 世界中医药,2018,13(12):2975-2979. doi: 10.3969/j.issn.1673-7202.2018.12.006